Health Care · Pharmaceutical Preparations

GENB Generate Biomedicines Inc SEC Filings & Insider Trading Activity 2026

company
CIK 210078224 filings

GENB at a glance

Generate Biomedicines Inc (GENB, SEC CIK 2100782) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Generate Biomedicines Inc (GENB) shares worth $202.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by ARNOLD FRANCES on October 29, 2026 of 11,409 shares at $16.19 per share.
  • In the last 90 days, GENB insiders reported 0 open-market purchases ($0) and 2 open-market sales ($201K) on Form 4, a net sale of $201K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 2 sells
Net −$201K
13F holders
22 funds
$202.8M · +1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material-change statement, but 2026 filing adds Zealand collaboration: $30.0 million upfront payment extends funding into first half of 2028
  • Regulatory risk: EU AI Act provisions effective August 2, 2026, imposing data quality, transparency, monitoring and oversight obligations
  • Clinical risk: GB-0895 Phase 3 severe-asthma trials use one 300 mg dose despite FDA and EMA dose-ranging recommendations
  • Operational risk: GB-0895 transition to autoinjector and pre-filled syringe may require bridging studies or repeat trials
  • Financial risk: Nine-month net loss $216.6 million and accumulated deficit $892.7 million as of September 30, 2026

Management Discussion & Analysis

  • Collaboration revenue $4.2M, down $5.4M from $9.6M YoY, as Novartis and Amgen obligations near completion
  • Net loss $87.7M vs $60.0M YoY, operating margin -2,168.4% vs -651.7% YoY
  • GB-0895 highest-spending program, R&D costs $37.1M vs $12.4M YoY; discovery programs lowest at $3.2M vs $10.2M
  • Operating cash outflow $193.2M, investing outflow $170.3M, financing inflow $381.8M, including IPO proceeds
  • Cash, equivalents and marketable securities $404.2M, funding expected into first half of 2028 including Zealand’s $30.0M upfront payment

AI summary of the GENB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing the company’s detailed results and management commentary

Item EX-99.1: Item EX-99.1

  • GB-0895 Phase 3 asthma trials evaluate 300 mg every 26 weeks, with six-month biomarker suppression supporting twice-yearly dosing
  • Zealand deal adds $30 million upfront, up to $35 million early milestones, and nearly $1.2 billion potential milestones plus tiered royalties
Filed Aug 26, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • ERS posters disclose ongoing GB-0895 clinical-trial results in severe asthma and COPD
  • Data support potential twice-yearly subcutaneous dosing for asthma patients
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Generate Biomedicines’ financial results for the quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q2 2026 revenue $6.3M, down from $10.1M, signaling lower collaboration activity from Amgen and Novartis
  • Net loss $67.3M, versus $56.7M, as R&D increased to $64.3M for Phase 3 asthma investment

AI summaries of GENB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for GENB

Don't miss the next GENB filing

  • Alerts as it files. A push when GENB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GENB, by share count.
  • Ask anything. An AI agent that reads every GENB filing and answers with sources.

GENB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
ARNOLD FRANCESSellOct 29, 2026$16.19
ARNOLD FRANCESSellSep 1, 2026$16.00
Nally MichaelBuyMar 4, 2026$12.00
AFEYAN NOUBARBuyMar 2, 2026$16.00
AFEYAN NOUBARCMar 2, 2026-
AFEYAN NOUBARCMar 2, 2026-
AFEYAN NOUBARCMar 2, 2026-
AFEYAN NOUBARBuyMar 2, 2026$16.00

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate GENB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
GENB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$202.8M
Q2 202621$258.7M
Q1 202614$145.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 57 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

GENB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
4Nov 4, 2026--
4Sep 3, 2026--
8-KAug 26, 2026Analysis-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026-
8-KMay 7, 2026-
10-QMay 7, 2026-
4Mar 6, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
8-KMar 2, 2026Analysis-
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--

Related Health Care companies

All Health Care →

GENB SEC filings: frequently asked questions

Are GENB insiders buying or selling?

In the last 90 days, Generate Biomedicines Inc (GENB) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $200,735 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold GENB stock?

As of September 30, 2026, the largest Generate Biomedicines Inc (GENB) holders among the 13F filers tracked by SignalX were JPMorgan Chase & Co ($40.9 million), Vanguard Capital Management LLC ($33.6 million), ARK Investment Management ($29.5 million), BlackRock ($27.5 million), T. Rowe Price Group ($20.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did GENB report in its latest 8-K?

Generate Biomedicines Inc (GENB) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest GENB SEC filings?

Generate Biomedicines Inc (GENB) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 4, 2026.

What is GENB's SEC CIK number?

Generate Biomedicines Inc (GENB)'s SEC Central Index Key (CIK) is 2100782. EDGAR lists every GENB filing under that number.

Ask anything about GENB

The research agent reads GENB's filings, financials, insider trades and 13F holders, then answers with sources.